Search

918 Result(s)
Sort by

EMPRISE-interim-analysis

EMPRISE-interim-analysis

Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
SIRPα Cancer Immunology Research

SIRPα Cancer Immunology Research

Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Advances in vectored vaccines for poultry

Advances in vectored vaccines for poultry

Vaccine design technologies have made huge advances in recent years. One of the newer categories of vaccine, vectored vaccines, is overcoming challenges that conventional vaccines do not meet.
survodutide top-line results MASH fibrosis

survodutide top-line results MASH fibrosis

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Empowering smallholder farmers

Empowering smallholder farmers

The LastMile initiative improves health equity in remote areas of Africa, increasing access to animal health resources for underserved farming communities.
The status of schizophrenia care

The status of schizophrenia care

A closer look at the status of the schizophrenia care landscape, an often misunderstood mental health condition
BTD for GlyT1 in Schizophrenia

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Rethinking mental health care

Rethinking mental health care

Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
EFPIA disclosure

EFPIA disclosure

Disclosure of Boehringer Ingelheim affiliates in countries with EFPIA member associations.